Effects of sub-inhibitory concentrations of nafcillin, vancomycin, ciprofloxacin, and rifampin on biofilm formation of clinical methicillin-resistant Staphylococcus aureus .

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: ASM Press Country of Publication: United States NLM ID: 101634614 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2165-0497 (Electronic) Linking ISSN: 21650497 NLM ISO Abbreviation: Microbiol Spectr Subsets: MEDLINE
    • Publication Information:
      Original Publication: Washington, DC : ASM Press, 2013-
    • Subject Terms:
    • Abstract:
      Methicillin-resistant Staphylococcus aureus (MRSA) infections are often difficult to treat because of their biofilm-forming ability and antimicrobial resistance. We investigated the effects of sub-minimal inhibitory concentrations (MICs) of antibiotics on MRSA biofilm formation. Clinical MRSA isolates were grown with sub-MICs (1/256-1/2 × MICs) of nafcillin, vancomycin, ciprofloxacin, and rifampin. The biofilm biomass was measured using crystal violet staining. Of the 107 MRSA isolates tested, 63 (58.9%) belonged to sequence type 5 (ST5), and 44 (41.1%) belonged to ST72. The MIC 50 /MIC 90 values of nafcillin, vancomycin, ciprofloxacin, and rifampin were 256/512, 1/2, 64/512, and 0.008/0.03 mg/L, respectively. The sub-MICs of nafcillin, vancomycin, ciprofloxacin, and rifampin promoted biofilm formation in 75 (70.1%), 49 (45.8%), 89 (83.2%), and 89 (83.2%) isolates, respectively. At sub-MICs of nafcillin, the factors associated with strong biofilm induction were the ST5 strain ( P = 0.001) and agr dysfunction ( P = 0.005). For the sub-MICs of ciprofloxacin, the associated factors were the ST5 strain ( P = 0.002), staphylococcal protein A type t002 strain ( P < 0.001), and ciprofloxacin resistance ( P < 0.001). Among the sub-MICs of rifampin, only ST5 was associated with strong biofilm induction ( P = 0.006). Because the sub-MICs of rifampin were much lower than clinically relevant concentrations, we further tested the capability of biofilm induction in 0.03[Formula: see text]32 mg/L of rifampin. At these concentrations, rifampin-induced biofilm formation was rare in rifampin-susceptible MRSA [1.0% (1 of 100)] but common in rifampin-resistant MRSA [71.4% (5 of 7), P < 0.001]. Induction of biofilm biomass at sub-MICs of antibiotics is common in clinical MRSA isolates and is differentially affected by the MRSA strain and antibiotic class.
      Importance: Bacteria can be exposed to sub-MICs of antibiotics at the beginning and end of a dosing regimen, between doses, or during low-dose therapies. Growing evidence suggests that sub-MICs of antimicrobials can stimulate MRSA biofilm formation and alter the composition of the biofilm matrix. Pevious studies have found that sub-MICs of oxacillin, methicillin, and amoxicillin promote biofilm formation in some community-acquired MRSA (CA-MRSA). We evaluated biofilm induction by sub-MICs of four different classes of antibiotics in 44 CA-MRSA and 63 healthcare-associated MRSA (HA-MRSA) strains. Our study indicated that sub-MICs of nafcillin, vancomycin, ciprofloxacin, and rifampin frequently promote biofilm induction in clinical MRSA isolates. Strong biofilm induction in sub-MICs of nafcillin, ciprofloxacin, and rifampin was more frequent in HA-MRSA than in CA-MRSA. Antibiotic-induced biofilm formation depends on the antibiotic class, MRSA strain, and antibiotic resistance. Our results emphasize the importance of maintaining effective bactericidal concentrations of antibiotics to treat biofilm-related infections.
      Competing Interests: The authors declare no conflict of interest.
    • References:
      J Infect. 2007 Jun;54(6):539-44. (PMID: 17198732)
      Antimicrob Agents Chemother. 2019 Jan 29;63(2):. (PMID: 30455229)
      J Antimicrob Chemother. 2015 Apr;70(4):1185-92. (PMID: 25433004)
      Ann Intern Med. 1991 Nov 1;115(9):674-80. (PMID: 1929035)
      Microbiology (Reading). 2008 Aug;154(Pt 8):2265-2274. (PMID: 18667559)
      Infection. 2013 Apr;41(2):431-7. (PMID: 22987291)
      Joint Bone Spine. 2013 Jan;80(1):11-7. (PMID: 23332140)
      Res Microbiol. 2011 Jun;162(5):535-41. (PMID: 21402153)
      APMIS. 2007 Aug;115(8):891-9. (PMID: 17696944)
      J Antimicrob Chemother. 1994 Apr;33(4):845-8. (PMID: 8056703)
      mBio. 2012 Jul 31;3(4):e00198-12. (PMID: 22851659)
      J Clin Microbiol. 2000 Mar;38(3):1008-15. (PMID: 10698988)
      J Hosp Infect. 2020 Oct;106(2):295-302. (PMID: 32679053)
      J Korean Med Sci. 2021 Apr 26;36(16):e104. (PMID: 33904260)
      J Antimicrob Chemother. 2014 Oct;69(10):2841-7. (PMID: 25140577)
      Clin Microbiol Infect. 2015 Jun;21(6):568.e1-11. (PMID: 25677632)
      Antimicrob Agents Chemother. 2016 Sep 23;60(10):5957-67. (PMID: 27458233)
      J Infect Dis. 2014 Apr 15;209(8):1231-40. (PMID: 24403556)
      Infect Immun. 2016 May 24;84(6):1917-1929. (PMID: 27068096)
      Curr Protoc Pharmacol. 2010 Sep;Chapter 13:Unit 13A.8. (PMID: 22294365)
      Dose Response. 2013 Jul 25;12(1):152-61. (PMID: 24659939)
      J Clin Microbiol. 1999 Nov;37(11):3556-63. (PMID: 10523551)
      J Clin Microbiol. 2007 Dec;45(12):4021-6. (PMID: 17942660)
      Diagn Microbiol Infect Dis. 2011 May;70(1):112-8. (PMID: 21398072)
      Rev Infect Dis. 1983 Jul-Aug;5 Suppl 3:S543-8. (PMID: 6556711)
      Int J Artif Organs. 2011 Sep;34(9):737-51. (PMID: 22094552)
      J Med Microbiol. 2015 Apr;64(Pt 4):323-334. (PMID: 25670813)
      J Infect Dis. 2000 Dec;182(6):1688-93. (PMID: 11069241)
      Antimicrob Agents Chemother. 2007 Mar;51(3):888-95. (PMID: 17158933)
      Antimicrob Agents Chemother. 2019 Oct 22;63(11):. (PMID: 31451499)
      Antimicrob Agents Chemother. 2016 Apr 22;60(5):2639-51. (PMID: 26856828)
    • Grant Information:
      NRF-2018R1D1A1B07040831 Ministry of Science and ICT, South Korea (MSIT); RS-2023-00246999 Ministry of Science and ICT, South Korea (MSIT); HI23C0299 Ministry of Health and Welfare (MOHW)
    • Contributed Indexing:
      Keywords: Staphylococcus aureus; biofilm; ciprofloxacin; nafcilllin; rifampin; vancomycin
    • Accession Number:
      5E8K9I0O4U (Ciprofloxacin)
      6Q205EH1VU (Vancomycin)
      VJT6J7R4TR (Rifampin)
      4CNZ27M7RV (Nafcillin)
      0 (Anti-Bacterial Agents)
      0 (Bacterial Proteins)
    • Publication Date:
      Date Created: 20240423 Date Completed: 20240605 Latest Revision: 20240807
    • Publication Date:
      20240807
    • Accession Number:
      PMC11237638
    • Accession Number:
      10.1128/spectrum.03412-23
    • Accession Number:
      38651875